Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.
Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.
Ovid Therapeutics announced a strategic update, highlighting its focus on developing novel epilepsy treatments, including the anticipated clinical trial for OV329 in 2022. The company is restructuring to reduce its workforce by 20%, aiming to enhance operational efficiency and extend its cash runway beyond 2024. Financial results showed a revenue increase to $208.4 million for 2021, primarily from a one-time payment from Takeda. However, a net loss of $26 million was reported for Q4 2021. The company plans to continue disciplined business development, including licensing agreements for gaboxadol and ganaxolone.
Ovid Therapeutics (NASDAQ: OVID) announced participation in the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The virtual panel discussion will focus on orphan neurological disorders. A live webcast and an archived replay will be available on the Company's website.
Ovid's pipeline includes innovative treatments for seizures and rare neurological disorders, such as OV329, OV350, and OV882, among others. The company maintains a significant interest in the development of soticlestat, with ongoing Phase 3 trials.
Ovid Therapeutics has entered into an exclusive licensing agreement with Healx for the development of gaboxadol. Healx intends to explore gaboxadol as a combination therapy for Fragile X syndrome and other conditions. The licensing agreement includes milestone payments for Ovid based on Healx's clinical, regulatory, and commercial achievements. Ovid will also receive tiered royalties on gaboxadol sales. This collaboration aims to accelerate the discovery of treatments for rare diseases, particularly those caused by Fragile X syndrome, which currently lacks effective therapies.
Ovid Therapeutics has signed an exclusive licensing deal with AstraZeneca for a library of early-stage small molecules aimed at the KCC2 transporter, including lead candidate OV350. This initiative is intended to enhance Ovid's pipeline for anti-epileptic therapies. The agreement involves a $5 million upfront payment and $7.5 million in Ovid shares, with additional potential milestones totaling up to $203.5 million. OV350 has shown promising results in preclinical studies for resistant epilepsy forms, targeting neuronal hyperexcitability.
Ovid Therapeutics announced advancements in its business development program, aiming to enhance its pipeline of CNS medicines. The company is currently enrolling patients in two pivotal Phase 3 trials for soticlestat targeting Lennox-Gastaut and Dravet syndromes. As of Q3 2021, Ovid reported $201.8 million in cash and equivalents, with zero revenue compared to $6.9 million in Q3 2020. The company’s net loss narrowed to $11.4 million, improving from $16.4 million year-over-year. Ovid plans to submit three INDs in three years, with OV329 targeted for 2022.
Ovid Therapeutics Inc. (NASDAQ: OVID) has appointed Dr. Kevin Fitzgerald to its Board of Directors. Dr. Fitzgerald brings over 20 years of experience in drug discovery, currently serving as Chief Scientific Officer at Alnylam Pharmaceuticals. His expertise in transforming scientific innovations into commercial medicines is expected to enhance Ovid's neuroscience development programs. Ovid focuses on developing therapies for rare neurological diseases, and Fitzgerald's addition is anticipated to strengthen the company's strategic approach in targeting central nervous system disorders.
Ovid Therapeutics (NASDAQ: OVID) announced a virtual presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13, 2021, at 7:00 a.m. EDT. The event will feature on-demand viewing, accessible through the company's website. Ovid is focused on developing treatments for neurological diseases, with a pipeline that includes OV329 for seizures related to Tuberous Sclerosis Complex, OV882 for Angelman syndrome, and OV815 for KIF1A associated neurological disorders. The company also has significant interests in soticlestat, currently under development for Dravet syndrome and Lennox-Gastaut syndrome.
Ovid Therapeutics reported zero revenue for Q2 2021 and a net loss of $15.8 million, improving from a $22.6 million loss in Q2 2020. The company ended the quarter with $212.2 million in cash. Operating expenses were $14.3 million, with adjusted operating expenses of $10.0 million, aligning with guidance. Leadership appointments aim to enhance its neuroscience focus, including Dr. Michael Poole to the board. Ovid terminated a previous agreement with Takeda for soticlestat, transferring R&D responsibilities while retaining milestone and royalty rights.
Ovid Therapeutics (NASDAQ: OVID) announced significant leadership changes aimed at advancing its neuroscience initiatives. Dr. Michael Poole joins the Board, bringing over 30 years of expertise. Dr. Claude Nicaise has been appointed Head of R&D, while Jason Tardio becomes Chief Operating Officer. The company is focusing on early-stage development and has reduced its workforce by 25% to streamline operations. Dr. Amit Rakhit transitions to the Scientific and Clinical Advisory Board after contributing significantly to Ovid's management team.
Ovid Therapeutics announced its participation in the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021, at 9:30 a.m. ET. The presentation will be conducted virtually, and interested individuals can access a live webcast on the Company's website. An archived replay will be available afterward. Ovid is focused on developing treatments for rare neurological diseases, featuring a pipeline that includes therapies for Tuberous Sclerosis Complex, Angelman syndrome, and other conditions.